458 related articles for article (PubMed ID: 11744721)
1. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein.
Cole NB; Murphy DD; Grider T; Rueter S; Brasaemle D; Nussbaum RL
J Biol Chem; 2002 Feb; 277(8):6344-52. PubMed ID: 11744721
[TBL] [Abstract][Full Text] [Related]
2. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
3. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
Li J; Uversky VN; Fink AL
Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
[TBL] [Abstract][Full Text] [Related]
4. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.
Wood SJ; Wypych J; Steavenson S; Louis JC; Citron M; Biere AL
J Biol Chem; 1999 Jul; 274(28):19509-12. PubMed ID: 10391881
[TBL] [Abstract][Full Text] [Related]
5. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Conway KA; Harper JD; Lansbury PT
Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
[TBL] [Abstract][Full Text] [Related]
6. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein.
Choi W; Zibaee S; Jakes R; Serpell LC; Davletov B; Crowther RA; Goedert M
FEBS Lett; 2004 Oct; 576(3):363-8. PubMed ID: 15498564
[TBL] [Abstract][Full Text] [Related]
7. Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease.
Mezey E; Dehejia AM; Harta G; Tresser N; Suchy SF; Nussbaum RL; Brownstein MJ; Polymeropoulos MH
Mol Psychiatry; 1998 Nov; 3(6):493-9. PubMed ID: 9857974
[TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons.
Saha AR; Hill J; Utton MA; Asuni AA; Ackerley S; Grierson AJ; Miller CC; Davies AM; Buchman VL; Anderton BH; Hanger DP
J Cell Sci; 2004 Mar; 117(Pt 7):1017-24. PubMed ID: 14996933
[TBL] [Abstract][Full Text] [Related]
9. Enhanced oligomerization of the alpha-synuclein mutant by the Cu,Zn-superoxide dismutase and hydrogen peroxide system.
Kang JH; Kim KS
Mol Cells; 2003 Feb; 15(1):87-93. PubMed ID: 12661766
[TBL] [Abstract][Full Text] [Related]
10. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry.
Braak H; Sandmann-Keil D; Gai W; Braak E
Neurosci Lett; 1999 Apr; 265(1):67-9. PubMed ID: 10327208
[TBL] [Abstract][Full Text] [Related]
11. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins.
Ostrerova N; Petrucelli L; Farrer M; Mehta N; Choi P; Hardy J; Wolozin B
J Neurosci; 1999 Jul; 19(14):5782-91. PubMed ID: 10407019
[TBL] [Abstract][Full Text] [Related]
12. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
Narhi L; Wood SJ; Steavenson S; Jiang Y; Wu GM; Anafi D; Kaufman SA; Martin F; Sitney K; Denis P; Louis JC; Wypych J; Biere AL; Citron M
J Biol Chem; 1999 Apr; 274(14):9843-6. PubMed ID: 10092675
[TBL] [Abstract][Full Text] [Related]
13. Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases.
Kahle PJ; Haass C; Kretzschmar HA; Neumann M
J Neurochem; 2002 Aug; 82(3):449-57. PubMed ID: 12153470
[No Abstract] [Full Text] [Related]
14. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain.
Kahle PJ; Neumann M; Ozmen L; Muller V; Jacobsen H; Schindzielorz A; Okochi M; Leimer U; van Der Putten H; Probst A; Kremmer E; Kretzschmar HA; Haass C
J Neurosci; 2000 Sep; 20(17):6365-73. PubMed ID: 10964942
[TBL] [Abstract][Full Text] [Related]
15. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease.
El-Agnaf OM; Jakes R; Curran MD; Wallace A
FEBS Lett; 1998 Nov; 440(1-2):67-70. PubMed ID: 9862427
[TBL] [Abstract][Full Text] [Related]
16. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.
Jensen PH; Nielsen MS; Jakes R; Dotti CG; Goedert M
J Biol Chem; 1998 Oct; 273(41):26292-4. PubMed ID: 9756856
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity.
Zhou W; Freed CR
J Biol Chem; 2004 Mar; 279(11):10128-35. PubMed ID: 14699135
[TBL] [Abstract][Full Text] [Related]
18. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein.
Bussell R; Eliezer D
Biochemistry; 2004 Apr; 43(16):4810-8. PubMed ID: 15096050
[TBL] [Abstract][Full Text] [Related]
19. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
Spillantini MG; Goedert M
Ann N Y Acad Sci; 2000; 920():16-27. PubMed ID: 11193145
[TBL] [Abstract][Full Text] [Related]
20. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.
Iwatsubo T
J Neurol; 2003 Oct; 250 Suppl 3():III11-4. PubMed ID: 14579119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
